Fracture risk in metastatic breast cancer patients treated with CDK 4/6 inhibitors and endocrine therapy
{{output}}
Purpose: Investigate skeletal morbidity (SM) in metastatic breast cancer (MBC) patients undergoing CDK4/6 inhibitors (CDK4/6is) and endocrine therapy (ET). Method... ...
